The average Adjusted Symptom Score, a new primary efficacy end-point for specific allergen immunotherapy trials Clinical & Experimental Allergy 42
Article first published online: 20 APR 2012 | DOI: 10.1111/j.1365-2222.2012.03991.x
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.